Charity Partners visit Leukaemia Centre

29th January 2014

Deloitte | The Binding Site | Hotel Indigo


Last week staff from a number of Cure Leukaemia’s charity partners took time out from their normal working Friday to visit the Centre for Clinical Haematology at the Queen Elizabeth Hospital.

The group included Sheila Newbury the Regional Corporate Responsibility Manager at Deloitte Birmingham, Emma Ramsey Head of Human Resources at The Binding Site along with Michelle Smith and Alex Aldea from recently announced Partners, Hotel Indigo Birmingham.

Co-founder of Cure Leukaemia Professor Charlie Craddock conducted a carefully guided tour of the Centre where our Partners got to see firsthand where the money goes that they, and their companies raise. Professor Charlie Craddock spoke about the past 10 years of Cure Leukaemia and the strides that they have made in finding a cure for this terrible disease before introducing them to patients in clinic as well as staff who are funded by Cure Leukaemia.

Having chosen Cure Leukaemia as their offices chosen charity, Deloitte Birmingham have raised over £40,000 in less than 6 months, whilst The Binding Site is Cure Leukaemia’s first charity partner to introduce payroll donations a method many employees have already signed up to. Our newest partners Hotel Indigo Birmingham are the first charity partners to sign up for 2 years and plan to host a number of new ideas and initiatives in the coming months.

 

< Back to List

What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell